Basic Research Support for the CCR

CCR的基础研究支持

• 批准号: 7970004
• 负责人: Robert Wiltrout
• 金额: $ 105.07万
• 依托单位: DIVISION OF BASIC SCIENCES - NCI
• 依托单位国家: 美国
• 资助国家: 美国
• 起止时间: 至
• 项目状态: 未结题
• 来源: https://reporter.nih.gov/project-details/7970004
• 关键词: Acquired Immunodeficiency Syndrome; Algorithms; Animal Technicians; Apoptotic; Area; Arts; Autoimmune Diseases; Basic Science; Biochemical; Biological Assay; Breast; CD4 Positive T Lymphocytes; Cancer Research Project; Cell physiology; Cell surface; Cells; Chemistry; Chronic; Clinical; Communicable Diseases; Comparative Carcinogenesis; Complex; Contrast Media; Development; Disease; Drug Delivery Systems; Drug resistance; Embryonic Development; Epigenetic Process; Epithelial; Event; Genetic; Genomics; Glioma; Glycobiology; Growth; HIV; HLA Antigens; Hematopoiesis; Human; Human Resources; Human T-Cell Leukemia Viruses; Immune response; Immunogenetics; Immunologic Deficiency Syndromes; Immunotherapy; Inflammation; Information Technology; Interleukins; Laboratories; Laboratory Animals; Laboratory Research; MHC Class II Genes; Malignant Neoplasms; Medical Imaging; Microarray Analysis; Mission; Molecular; Molecular Biology; Molecular Target; Mus; NCI Center for Cancer Research; National Cancer Institute; Natural Killer Cells; Natural Products Chemistry; Neoplasm Metastasis; Neoplasms; Nitric Oxide; Pathogenesis; Pathway interactions; Pattern; Play; Predisposition; Prevention therapy; Prostate; Protein Chemistry; Proteins; Qualifying; Reaction; Regulation; Renal Cell Carcinoma; Renal carcinoma; Research; Research Support; Resistance; Reverse Transcription; Ribosomes; Role; Scientist; Screening procedure; Signal Pathway; Signal Transduction; Stem cells; Stress; Structure; Study Section; Susceptibility Gene; Technical Expertise; Urologic Oncology; Vaccines; Viral Antigens; Viral Proteins; Virus; anticancer research; base; cancer diagnosis; cancer genetics; cancer prevention; cancer stem cell; cancer therapy; carcinogenesis; cell growth; cellular imaging; design; epidemiology study; genetic epidemiology; glycosyltransferase; group support; in vivo; metabolic abnormality assessment; multidisciplinary; nanobiology; novel; programs; protein protein interaction; ras Proteins; receptor; self-renewal; stem cell biology; structural biology; tumorigenesis; vaccine development

The Basic Research Program provides scientific and technical expertise to the Center for Cancer Research (CCR) in areas ranging from cancer and human immunodeficiency virus (HIV)/acquired immunodeficiency syndrome (AIDS), to the basic cellular processes underlying cancer, infectious diseases, and autoimmune disorders. Research topics supported by the Basic Research Program include: -Investigating ways in which novel, molecularly targeted cancer therapies can be used in combination with immunotherapy (Molecular Immunotherapy Section, Cancer and Inflammation Program). -Understanding the genetic basis for resistance or susceptibility to disease conferred by human leukocyte antigen (HLA) class I and class II genes and the role of natural killer (NK) cells in the innate immune response (HLA Immunogenetics Section, Cancer and Inflammation Program). -Characterizing the receptors that activate natural killer (NK) cells and the innate immune response (Cytotoxic Cell Studies Group, Cancer and Inflammation Program). -Examining the association of chronic inflammation with epithelial carcinogenesis (Interleukin In Vivo Studies Section, Cancer and Inflammation Program). -Defining the receptor complex of CD4+ cells, a primary target of human T-cell leukemia virus type I (HTLV Section, Cancer and Inflammation Program). -Identifying and defining the molecular events that regulate lineage commitment and terminal differentiation of hemotopoietic stem cells (Hematopoiesis and Stem Cell Biology Section, Laboratory of Cancer Prevention). -Defining the cell surface markers, metastasis ability, and pathways for growth and self-renewal, of cancer stem cells from prostate, breast, glioma, and renal cell carcinomas (Cancer Stem Cell Section, Laboratory of Cancer Prevention). -Studying the role that epigenetic regulation plays in cellular differentiation, embryonic development, and tumorigenesis (Epigenetics Section, Laboratory of Cancer Prevention). -Understanding the structure and function of glycosyltransferases and developing novel glycosyltransferases for targeted drug delivery and contrast agents for medical imaging (Structural Glycobiology Section, CCR Nanobiology Program). -Developing highly efficient, state-of-the-art algorithms to discover the structural patterns of proteins and predict molecular associations (i.e., protein-protein interactions) in support of nanodesign for cancer diagnosis, therapy, and prevention (Computational Structural Biology Group, CCR Nanobiology Program). -Support in bioassay development and screening, natural products chemistry, protein chemistry, molecular biology, and high-content cellular imaging to facilitate multidisciplinary, molecular targets discovery research (Molecular Targets Laboratory). -Basic and applied chemistry support for studies characterizing the reactions of the bioregulatory agent nitric oxide (NO) with organic compounds (Chemistry Section, Laboratory of Comparative Carcinogenesis). -Microarray analysis aimed at determining the role of K-ras protein in controlling cell growth and differentiation (Cellular Pathogenesis Section, Laboratory of Comparative Carcinogenesis). -Characterizing the inductive signaling pathways involved in metanephric blastemal cell specification/patterning to help define potential targets of carcinogenesis (Differentiation and Neoplasia Section, Laboratory of Comparative Carcinogenesis). -Studying the metabolic modulation of proliferative, apoptotic, and stress-related signaling in carcinogenesis and cancer susceptibility (Cancer Susceptibility Section, Laboratory of Comparative Carcinogenesis). -Developing new molecular approaches for genetic epidemiology studies (Genetic Epidemiology Section, Laboratory of Genomic Diversity). -Design and development of genetic, biochemical, and structural studies of medically important viral proteins (Reverse Transcription and Molecular Biology Group). -Support for studies focusing on retroviral vaccine development, immune response to viral antigens, and the role of structural RNAs and proteins in the function of ribosomes (Reverse Transcription and Molecular Biology Group). -Discovery and characterization of renal carcinoma susceptibility genes (Urologic Oncology Research Group, Urologic Oncology Branch).

基础研究计划为中心提供科学和技术专业知识 癌症研究中心（CCR）的研究领域包括癌症和人类免疫缺陷病毒 (HIV)艾滋病（艾滋病）的基本细胞过程 癌症、传染病和自身免疫性疾病。基础研究资助的研究课题 研究计划包括：-研究新的分子靶向癌症的方法 治疗可以与免疫治疗联合使用（分子免疫治疗部分， 癌症和炎症计划）。- 了解耐药性的遗传基础，或 对人类白细胞抗原（HLA）I类和II类赋予的疾病的易感性 基因和自然杀伤（NK）细胞在先天免疫应答（HLA）中的作用 免疫遗传学部分，癌症和炎症计划）。- 表征受体， 激活自然杀伤（NK）细胞和先天免疫应答（细胞毒性细胞研究 组，癌症和炎症计划）。- 检查慢性炎症的关联 与上皮癌发生（白细胞介素体内研究部分，癌症和炎症 程序）。- 定义CD 4+细胞的受体复合物，这是人类T细胞免疫的主要靶点。 白血病病毒I型（HTLV部分，癌症和炎症计划）。识别和 定义调节谱系定型和终末分化的分子事件， 造血干细胞（癌症研究室造血和干细胞生物学部分 预防）。- 确定细胞表面标志物、转移能力和生长途径 和自我更新，来自前列腺、乳腺、神经胶质瘤和肾细胞的癌症干细胞 癌（癌症干细胞科，癌症预防实验室）。- 学习角色 表观遗传调控在细胞分化、胚胎发育和 肿瘤发生（表观遗传学部分，癌症预防实验室）。- 了解 糖基转移酶的结构和功能以及开发用于 用于医学成像的靶向药物递送和造影剂（结构糖生物学 部分，CCR纳米生物学计划）。- 开发高效、先进的算法 为了发现蛋白质的结构模式并预测分子关联（即， 蛋白质-蛋白质相互作用）支持癌症诊断、治疗和治疗的纳米设计 预防（计算结构生物学组，CCR纳米生物学计划）。- 支助 生物测定开发和筛选，天然产物化学，蛋白质化学，分子 生物学和高内容细胞成像，以促进多学科，分子靶点 分子靶向实验室（Molecular Targets Laboratory）- 基础和应用化学支持， 生物调节剂一氧化氮（NO）与有机物反应的特征研究 化合物（化学部分，比较致癌实验室）。- 微阵列分析 目的是确定K-ras蛋白在控制细胞生长和分化中的作用， （细胞发病机理部分，比较致癌作用实验室）。- 描述 诱导信号通路参与后肾胚基细胞特化/模式化 以帮助确定致癌作用的潜在靶点（分化和瘤形成部分， 比较致癌实验室（Laboratory of Comparative Carcinogenesis）。- 研究代谢调节 癌发生和癌症中的增殖、凋亡和应激相关信号传导 易感性（癌症易感性部分，比较致癌实验室）。 - 为遗传流行病学研究开发新的分子方法（遗传流行病学 基因组多样性实验室（Laboratory of Genomic Diversity）- 设计和开发遗传、生物化学、 和医学上重要的病毒蛋白质的结构研究（逆转录和 分子生物学组）。- 支持以研制逆转录病毒疫苗为重点的研究， 对病毒抗原的免疫反应，以及结构RNA和蛋白质在其中的作用 核糖体的功能（逆转录和分子生物学组）。- 发现和 肾癌易感基因的表征（UrologicOncologyResearch Group， 泌尿肿瘤学分支）。